Pfizer develops new drugs in 11 therapeutic areas

In a Research & Development (R&D) meeting, Jeffrey B. Kindler, Pfizer’s chief executive officer, said that the company’s fundamental objective is to create a broad and very diversified stream of new products that will, year after year, drive its growth and enhance the value of its shareholders’ investment.

 

Pfizer now has more candidates, more trials, and more programs than it has ever had, a total of 242 programs spanning 11 therapeutic areas.

 

Dr. John LaMattina, president of Pfizer Global Research and Development, said important research programs are underway in atherosclerosis, oncology, diabetes, obesity, rheumatoid arthritis, HIV, schizophrenia, liver disease and Alzheimer’s, among others.

 

"We now expect that our Phase 3 portfolio will grow dramatically and may even triple from 2006 to 2009. This will give us a steady stream of new and important products from our internal development pipeline. We are targeting four a year – starting in 2011," he added.

 

Areas of concentration include:

 

l A cardiovascular, metabolic and endocrine disease portfolio with five main areas of focus – atherosclerosis, obesity, diabetes, bone and muscle health, and thrombosis.

 

l Pfizer’s emerging oncology portfolio, where the company has several potential first-in-class agents. Pfizer has made a major investment in oncology and is moving quickly to build on the success of its launch of Sutent earlier this year with an impressive array of novel agents.

 

l Pfizer’s neuroscience portfolio, where the company has an industry-leading track record and a portfolio of new drug targets in areas of critical medical need, including Alzheimer’s disease, pain, cognition and ADHD, depression and anxiety, and sleep.

 

l A strong program in infectious diseases, where Pfizer is targeting key bacterial agents and key viral diseases. The most advanced new drug candidate in this therapeutic area is maraviroc, a CCR5 inhibitor that Pfizer plans to file next month for use in treatment-experienced HIV patients.

 

l CP-690,550, a compound that targets Janus Kinase 3, associated with immunosuppression.

 

 

Source: Manila Bulletin Online

http://www.mb.com.ph/issues/2007/01/16/HLTH2007011684631.html